NovaBridge Biosciences·4

Jun 2, 6:46 PM ET

Xu Cong Claire 4

4 · NovaBridge Biosciences · Filed Jun 2, 2026

Research Summary

AI-generated summary of this filing

Updated

NovaBridge (NBP) SVP Claire Xu Exercises/Converts Shares and Sells 3,494

What Happened

  • Claire Xu (Xu Cong), Senior Vice President, Clinical Development, converted/exercised derivative awards on May 30, 2026 and then sold 3,494 shares in an open-market transaction on June 1, 2026 for $3.94 each, generating $13,766 in proceeds.
  • The filing shows two derivative conversion/exercise entries (May 30): 9,382 shares acquired (exercise/conversion) and 4,079 shares recorded as disposed with $0 proceeds (consistent with shares withheld/surrendered for taxes or similar settlement of a derivative/RSU). The open-market sale on June 1 disposed of 3,494 shares at $3.94 per share for $13,766.

Key Details

  • Transaction dates and prices:
    • May 30, 2026 — exercise/conversion of 9,382 shares (derivative; acquisition).
    • May 30, 2026 — conversion/disposition of 4,079 derivative shares at $0.00 (likely tax withholding or share surrender).
    • June 1, 2026 — open-market sale of 3,494 shares at $3.94 each for $13,766 total.
  • Shares reported after these transactions: filing footnotes report holdings in ADS terms (see below); the filing lists holdings represented by ~127,673 ADSs (per footnote disclosures).
  • Notable footnotes:
    • The company’s ordinary shares may be represented by American Depositary Shares (ADS). Per filing, 10 ADSs = 23 ordinary shares.
    • Several entries and holdings are reported in ADSs (examples in footnotes: 4,079 ADSs; 1,519 ADSs; 126,154–127,673 ADSs).
    • Each restricted stock unit (RSU) represents a contingent right to receive one ADS; a prior RSU grant (May 30, 2024) of 65,270 RSUs vests over four years (one-quarter after one year, then quarterly).
    • One disposal entry shows $0 proceeds, which commonly reflects shares withheld or surrendered to satisfy tax withholding on an exercise/RSU conversion.
  • Filing: Form 4 was filed June 2, 2026, reporting transactions through May 30, 2026.

Context

  • Derivative conversion/exercise: The May 30 entries reflect conversion/exercise of company-granted awards (options/RSUs). Some shares appear to have been surrendered/withheld (zero proceeds) — a typical administrative step to cover taxes rather than an additional sale for cash.
  • Sale vs. purchase: The only cash transaction here was a small open-market sale (3,494 shares for $13,766). Routine sales to cover taxes or diversify holdings are common; purchases would typically be viewed as a more direct bullish signal.
  • ADS note for retail investors: Because NovaBridge uses ADSs, reported ADS counts and per‑ADS prices can differ from per‑ordinary‑share figures — the filing includes converted ADS pricing and ADS-equivalent holdings for clarity.

Insider Transaction Report

Form 4
Period: 2026-05-30
Xu Cong Claire
SVP, Clinical Development
Transactions
  • Exercise/Conversion

    Ordinary Shares

    [F1][F2][F3][F4]
    2026-05-30+9,382293,648 total
  • Sale

    Ordinary Shares

    [F1][F5][F6][F7]
    2026-06-01$3.94/sh3,494$13,766290,154 total
  • Exercise/Conversion

    Restricted Share Units

    [F3][F8][F9][F1]
    2026-05-304,07932,637 total
    Ordinary Shares (4,079 underlying)
Footnotes (9)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
  • [F2]Reported securities are represented by 4,079 ADSs.
  • [F3]Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
  • [F4]Reported securities are represented by 127,673 ADSs.
  • [F5]Reported securities are represented by 1,519 ADSs.
  • [F6]Reported sales price represents the converted sales price of the ADSs of $1.71.
  • [F7]Reported securities are represented by 126,154 ADSs.
  • [F8]Reported securities represent ADSs.
  • [F9]On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.
Signature
/s/ Xi-Yong (Sean) Fu as attorney-in-fact|2026-06-02

Documents

1 file
  • 4
    form4-06022026_100655.xmlPrimary